← Laboratorios Farmaceuticos Rovi, S.A./ADR (LABFF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Laboratorios Farmaceuticos Rovi, S.A./ADR (LABFF)
Biotechnology · market cap $3.4B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) is a Spanish biotechnology company with 2,197 employees and a market capitalization of approximately $4.635 billion. Its lead pipeline asset, DMMET-01, is in Phase 3 development for Type 2 Diabetes, with a secondary asset, Nimotuzumab, in Phase 2 for Diffuse Intrinsic Brainstem Gliomas. Key financial details including cash position, revenue, and net debt are not available in the provided data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DMMET-01 | Phase 3 | Diabetes Type 2 |
| Nimotuzumab | Phase 2 | Diffuse Intrinsic Brainstem Gliomas |
Price & technical context
3-month
-25.9%
6-month
-25.9%
12-month
-25.9%
52-wk range
$67.17–$90.61
vs 50-day MA
-8.9%
vs 200-day MA
-22.2%
Realized vol
29.9%
Max drawdown
-25.9%
Daily closes through 2026-09-22. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LABFF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.